CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

8298	Companies
114933	Keywords
55342	Articles
62466	Press releases

Home
Companies
CROSSJECT

BRIEF

published on 08/22/2024 at 07:35, 2 months 30 days ago

Crossject to Participate in HC Wainwright’s 26th Annual Global Investment Conference

Investment Conference Crossject ZENEO® HC Wainwright
PRESS RELEASE

published on 08/22/2024 at 07:30, 2 months 30 days ago

Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
Crossject to present at H.C. Wainwright 26th Annual Global Investment Conference on September 9th-11th, 2024, showcasing their needle-free auto-injector ZENEO®

H.C. Wainwright Crossject Needle-free Auto-injector ZENEO® Global Investment Conference
BRIEF

published on 07/18/2024 at 07:35, 4 months 3 days ago

Crossject Achieves Key ZEPIZURE® Manufacturing Milestone

Crossject ZEPIZURE® Manufacturing Milestone FDA EUA ZENEO®
PRESS RELEASE

published on 07/18/2024 at 07:30, 4 months 3 days ago

Crossject achieves key ZEPIZURE® manufacturing milestone
Crossject achieves key ZEPIZURE manufacturing milestone with successful completion of new registration batch at Eurofins' qualified facility, supporting EUA timelines

Emergency Use Authorization Crossject ZEPIZURE Eurofins Manufacturing Milestone
BRIEF

published on 06/26/2024 at 07:35, 4 months 25 days ago

Crossject highlights the potential of ZEPIZURE® following RAMPART and bioequivalence studies

Crossject ZEPIZURE® Midazolam RAMPART Study Epileptic Seizures
PRESS RELEASE

published on 06/26/2024 at 07:30, 4 months 25 days ago

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
Crossject provides insights on ZEPIZURE® potential in light of RAMPART and its bioequivalence study. IM midazolam favored over IV lorazepam for emergency epilepsy management

Crossject ZEPIZURE RAMPART Study Bioequivalence Study Emergency Epilepsy Management
BRIEF

published on 06/18/2024 at 12:35, 5 months 3 days ago

Crossject: Information relating to the total number of voting rights and shares making up the share capital

Share Capital Voting Rights AMF Crossject Specialized Pharmacy
BRIEF

published on 06/13/2024 at 09:41, 5 months 8 days ago

Crossject: Information on the number of voting rights and shares

Share Capital Voting Rights Actions 2024 Crossject
BRIEF

published on 06/12/2024 at 07:35, 5 months 9 days ago

Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer

Crossject ZEPIZURE® Dan Chiche Medical Director
PRESS RELEASE

published on 06/12/2024 at 07:30, 5 months 9 days ago

Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America, strengthening leadership team and expanding presence in U.S. Supports ZEPIZURE® regulatory milestones targeting in 2025

North America Chief Medical Officer Crossject ZEPIZURE Dan Chiche

Accesswire

Published on 11/21/2024 at 14:15, 5 minutes ago

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 20 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 20 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 20 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 20 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:16, 4 minutes ago

EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 5 minutes ago

ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 20 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 1 hour 5 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 45 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 22 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 35 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 35 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE